Hims & Hers Health (NYSE:HIMS) Upgraded at Zacks Research

Hims & Hers Health (NYSE:HIMS) was upgraded by research analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a note issued to investors on Monday,Zacks.com reports.

HIMS has been the subject of a number of other research reports. Wall Street Zen cut Hims & Hers Health from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. JPMorgan Chase & Co. lowered their price objective on Hims & Hers Health from $35.00 to $33.00 and set an “overweight” rating on the stock in a research report on Tuesday, May 12th. Canaccord Genuity Group increased their target price on shares of Hims & Hers Health from $32.00 to $40.00 and gave the stock a “buy” rating in a report on Wednesday, July 1st. Weiss Ratings cut shares of Hims & Hers Health from a “hold (c)” rating to a “sell (d)” rating in a research note on Tuesday, May 12th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and set a $25.00 price target on shares of Hims & Hers Health in a report on Tuesday, May 5th. Four equities research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $30.70.

Hims & Hers Health Trading Up 2.2%

Shares of Hims & Hers Health stock opened at $35.14 on Monday. The company’s fifty day simple moving average is $29.69 and its 200-day simple moving average is $26.34. The stock has a market capitalization of $8.13 billion, a PE ratio of -390.43, a P/E/G ratio of 96.75 and a beta of 2.35. Hims & Hers Health has a 1-year low of $13.74 and a 1-year high of $70.43. The company has a debt-to-equity ratio of 2.18, a current ratio of 1.69 and a quick ratio of 1.56.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings data on Monday, May 11th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of $0.04 by ($0.44). Hims & Hers Health had a positive return on equity of 6.10% and a negative net margin of 0.56%.The company had revenue of $608.10 million during the quarter, compared to analysts’ expectations of $616.84 million. During the same quarter last year, the company earned $0.20 earnings per share. The company’s revenue for the quarter was up 3.8% on a year-over-year basis. As a group, equities analysts anticipate that Hims & Hers Health will post 0.03 earnings per share for the current year.

Insider Activity at Hims & Hers Health

In other news, COO Michael Chi sold 14,027 shares of the business’s stock in a transaction on Wednesday, June 17th. The shares were sold at an average price of $31.50, for a total value of $441,850.50. Following the transaction, the chief operating officer owned 432,124 shares of the company’s stock, valued at approximately $13,611,906. The trade was a 3.14% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director David B. Wells acquired 48,400 shares of the company’s stock in a transaction on Tuesday, May 26th. The shares were bought at an average cost of $24.23 per share, with a total value of $1,172,732.00. Following the acquisition, the director directly owned 224,417 shares in the company, valued at approximately $5,437,623.91. The trade was a 27.50% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders have sold 167,161 shares of company stock worth $5,041,152 in the last three months. Corporate insiders own 11.76% of the company’s stock.

Institutional Trading of Hims & Hers Health

Large investors have recently added to or reduced their stakes in the company. Versant Capital Management Inc boosted its position in shares of Hims & Hers Health by 801.2% during the 2nd quarter. Versant Capital Management Inc now owns 748 shares of the company’s stock valued at $26,000 after acquiring an additional 665 shares during the last quarter. MassMutual Private Wealth & Trust FSB lifted its position in Hims & Hers Health by 70.0% during the second quarter. MassMutual Private Wealth & Trust FSB now owns 775 shares of the company’s stock valued at $27,000 after purchasing an additional 319 shares during the last quarter. Flagship Harbor Advisors LLC purchased a new position in shares of Hims & Hers Health in the 4th quarter worth $28,000. Binnacle Investments Inc bought a new stake in shares of Hims & Hers Health in the 3rd quarter worth about $28,000. Finally, Bogart Wealth LLC raised its position in shares of Hims & Hers Health by 235.8% during the 4th quarter. Bogart Wealth LLC now owns 900 shares of the company’s stock valued at $29,000 after buying an additional 632 shares in the last quarter. Institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.